secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibrx Biosciences, Inc. (INBX)
CIK:        0002007919
Form:       8-K
Filed at:   2026-08-13T20:10:15+00:00
Accession:  0002007919-26-000044
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibrx Q2 net loss $36.7M; cash $219.5M post $100M Oxford loan; ozekibart PDUFA Apr 2027
--------------------------------------------------------------------------------

- Net loss $36.7M ($2.34/share) vs $28.7M ($1.85/share) in Q2 2025; no revenue vs $1.3M prior year.
- Cash $133.3M at June 30; $219.5M as of Aug 6 after $100M funded from $325M Oxford loan amendment.
- FDA accepted BLA for ozekibart in chondrosarcoma; PDUFA date April 14, 2027.
- INBRX-106 PFS data from Phase 2 HNSCC trial expected Q3 2026; new CRC cohorts initiated.
- R&D $23.9M, G&A $8.3M, up from $22.3M and $6.4M respectively.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2007919/000200791926000044/0002007919-26-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2007919/000200791926000044/inhibrx-20260813.htm
  HTML page:      https://secwatch.observer/filing/0002007919-26-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer